MAVATREP
Osteoarthritis, Knee
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
31 Active assets in the Osteoarthritis, Knee cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine Orthopaedic Arthroscopy Knee and Shoulder Clinic | Phase 4 | BBB |
Naproxen Pfizer | Phase 3 | BB |
Triamcinalone Mayo Clinic | Phase 4 | BB |
Remimazolam Seoul National University Hospital | Phase 4 | BB |
Bxcl501 Poznan University of Medical Sciences | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →